401 related articles for article (PubMed ID: 29053672)
1. Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.
Zhang RX; Zhang T; Chen K; Cheng J; Lai P; Rauth AM; Pang KS; Wu XY
J Vis Exp; 2017 Oct; (128):. PubMed ID: 29053672
[TBL] [Abstract][Full Text] [Related]
2. Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor.
Zhang RX; Cai P; Zhang T; Chen K; Li J; Cheng J; Pang KS; Adissu HA; Rauth AM; Wu XY
Nanomedicine; 2016 Jul; 12(5):1279-90. PubMed ID: 26772427
[TBL] [Abstract][Full Text] [Related]
3. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
4. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
5. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model.
Shuhendler AJ; Prasad P; Zhang RX; Amini MA; Sun M; Liu PP; Bristow RG; Rauth AM; Wu XY
Mol Pharm; 2014 Aug; 11(8):2659-74. PubMed ID: 24830351
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
9. A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells.
Prasad P; Cheng J; Shuhendler A; Rauth AM; Wu XY
Drug Deliv Transl Res; 2012 Apr; 2(2):95-105. PubMed ID: 25786718
[TBL] [Abstract][Full Text] [Related]
10. Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
Zhang T; Lip H; He C; Cai P; Wang Z; Henderson JT; Rauth AM; Wu XY
Adv Healthc Mater; 2019 Sep; 8(18):e1900543. PubMed ID: 31348614
[TBL] [Abstract][Full Text] [Related]
11. In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin.
Cheung RY; Rauth AM; Ronaldson PT; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2006 Apr; 62(3):321-31. PubMed ID: 16330194
[TBL] [Abstract][Full Text] [Related]
12. mPEGylated solanesol micelles as redox-responsive nanocarriers with synergistic anticancer effect.
Qin B; Liu L; Wu X; Liang F; Hou T; Pan Y; Song S
Acta Biomater; 2017 Dec; 64():211-222. PubMed ID: 28963017
[TBL] [Abstract][Full Text] [Related]
13. Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect.
Jia M; Li Y; Yang X; Huang Y; Wu H; Huang Y; Lin J; Li Y; Hou Z; Zhang Q
ACS Appl Mater Interfaces; 2014 Jul; 6(14):11413-23. PubMed ID: 24977925
[TBL] [Abstract][Full Text] [Related]
14. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
[TBL] [Abstract][Full Text] [Related]
15. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
[TBL] [Abstract][Full Text] [Related]
16. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
17. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
19. Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy.
Zhang P; Li J; Ghazwani M; Zhao W; Huang Y; Zhang X; Venkataramanan R; Li S
Biomaterials; 2015 Oct; 67():104-14. PubMed ID: 26210177
[TBL] [Abstract][Full Text] [Related]
20. HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles.
Alhareth K; Vauthier C; Gueutin C; Ponchel G; Moussa F
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 887-888():128-32. PubMed ID: 22341684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
